Abstract
Primary infection with Epstein–Barr virus (EBV) is usually asymptomatic and, in a normal host, EBV remains latent in B cells after primary infection for the remainder of life. Uncommonly, EBV can infect T or natural killer (NK) cells in a person with a defect in innate immunity, and EBV infection can cause unique systemic lymphoproliferative diseases (LPD) of childhood. Primary infection in young children can be complicated by hemophagocytic lymphohistiocytosis or fulminant systemic T‐cell LPD of childhood. Uncommonly, patients can develop chronic active EBV (CAEBV) disease‐type T/NK LPD, which includes CAEBV infection of the systemic form, hydroa vacciniforme‐like T‐cell LPD, and mosquito‐bite hypersensitivity. The clinical course of CAEBV disease‐type T/NK LPD can be smoldering, persistent or progressive, depending on the balance between viral factors and host immunity. Aggressive NK‐cell leukemia, hydroa vacciniforme‐like T‐cell lymphoma, or uncommonly extranodal NK/T‐cell lymphoma can develop in children and young adults with CAEBV disease‐type T/NK‐cell LPD. Extranodal T/NK‐cell lymphoma is a disease of adults, and its incidence begins to increase in the third decade and comprises the major subtype of T/NK LPD throughout life. Aggressive NK‐cell leukemia and nodal T/NK‐cell lymphoma of the elderly are fulminant diseases, and immune senescence may be an important pathogenetic factor. This review describes the current progress in identifying different types of EBV‐associated T/NK‐cell LPD and includes a brief presentation of data from Korea.

This publication has 108 references indexed in Scilit: